Literature DB >> 23027808

Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats.

Hisanori Matsui1, Akira Tanaka, Kotaro Yokoyama, Yoshihiro Takatsu, Kaori Ishikawa, Taiji Asami, Naoki Nishizawa, Atsuko Suzuki, Satoshi Kumano, Michiko Terada, Masami Kusaka, Chieko Kitada, Tetsuya Ohtaki.   

Abstract

Metastin/kisspeptin, a hypothalamic peptide, plays a pivotal role in controlling GnRH neurons. Here we studied the effect of chronic sc administration of two kisspeptin analogs, KISS1-305 and TAK-448, on hypothalamic-pituitary-gonadal function in male rats in comparison with a GnRH analogue leuprolide or bilateral orchiectomy (ORX). The prototype polypeptide, KISS1-305 (1-4 nmol/h), caused substantial elevations of plasma LH and testosterone, followed by abrupt reductions of both hormone levels. Notably, testosterone levels were reduced to castrate levels within 3 d and remained depleted throughout the 4-wk dosing period, an effect that was faster and more pronounced than leuprolide (1 nmol/h) dosing. KISS1-305 also reduced genital organ weight more profoundly than leuprolide. In mechanistic studies, chronic KISS1-305 administration only transiently induced c-Fos expression in GnRH neurons, suggesting that GnRH-neural response was attenuated over time. Hypothalamic GnRH content was reduced to 10-20% of control at 3 wk without any changes in Gnrh mRNA expression. Dosing with the investigational peptide TAK-448 was also studied to extend our understanding of hypothalamic-pituitary functions. Similar to ORX, TAK-448 (0.1 nmol/h) depleted testosterone and decreased GnRH content by 4 wk. However, in contrast to ORX, TAK-448 decreased gonadotropin levels in pituitary and plasma samples, implying the suppression of GnRH pulses. These results suggest that chronic administration of kisspeptin analogs disrupts endogenous kisspeptin signals to suppress intrinsic GnRH pulses, perhaps by attenuating GnRH-neural response and inducing continuous GnRH leakage from the hypothalamus. The potential utility of kisspeptin analogs as novel agents to treat hormone-related diseases, including prostate cancer, is discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23027808     DOI: 10.1210/en.2012-1388

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

Review 1.  The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction.

Authors:  Qinying Xie; Yafei Kang; Chenlu Zhang; Ye Xie; Chuxiong Wang; Jiang Liu; Caiqian Yu; Hu Zhao; Donghui Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

Review 2.  Advances in clinical applications of kisspeptin-GnRH pathway in female reproduction.

Authors:  Kai-Lun Hu; Zimiao Chen; Xiaoxue Li; Enci Cai; Haiyan Yang; Yi Chen; Congying Wang; Liping Ju; Wenhai Deng; Liangshan Mu
Journal:  Reprod Biol Endocrinol       Date:  2022-05-23       Impact factor: 4.982

Review 3.  Current and future applications of GnRH, kisspeptin and neurokinin B analogues.

Authors:  Robert P Millar; Claire L Newton
Journal:  Nat Rev Endocrinol       Date:  2013-07-02       Impact factor: 43.330

4.  Furin is the major proprotein convertase required for KISS1-to-Kisspeptin processing.

Authors:  Sitaram Harihar; Keke M Pounds; Tomoo Iwakuma; Nabil G Seidah; Danny R Welch
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

5.  A synthetic kisspeptin analog that triggers ovulation and advances puberty.

Authors:  C Decourt; V Robert; K Anger; M Galibert; J-B Madinier; X Liu; H Dardente; D Lomet; A F Delmas; A Caraty; A E Herbison; G M Anderson; V Aucagne; M Beltramo
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

6.  The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells.

Authors:  Mark P Labrecque; Mandeep K Takhar; Rebecca Nason; Stephanie Santacruz; Kevin J Tam; Shabnam Massah; Anne Haegert; Robert H Bell; Manuel Altamirano-Dimas; Colin C Collins; Frank J S Lee; Gratien G Prefontaine; Michael E Cox; Timothy V Beischlag
Journal:  Oncotarget       Date:  2016-04-26

7.  Effect of investigational kisspeptin/metastin analog, TAK-683, on luteinizing hormone secretion at different stages of the luteal phase in goats.

Authors:  Larasati Puji Rahayu; Mohammed El Behiry; Natsumi Endo; Tomomi Tanaka
Journal:  J Reprod Dev       Date:  2017-03-25       Impact factor: 2.214

8.  Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo.

Authors:  Xavier d'Anglemont de Tassigny; Channa N Jayasena; Kevin G Murphy; Waljit S Dhillo; William H Colledge
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

9.  Differential effects of continuous exposure to the investigational metastin/kisspeptin analog TAK-683 on pulsatile and surge mode secretion of luteinizing hormone in ovariectomized goats.

Authors:  Tomomi Tanaka; Satoshi Ohkura; Yoshihiro Wakabayashi; Takenobu Kuroiwa; Kiyosuke Nagai; Natsumi Endo; Akira Tanaka; Hisanori Matsui; Masami Kusaka; Hiroaki Okamura
Journal:  J Reprod Dev       Date:  2013-09-19       Impact factor: 2.214

10.  Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers.

Authors:  C N Jayasena; A N Comninos; G M K Nijher; A Abbara; A De Silva; J D Veldhuis; R Ratnasabapathy; C Izzi-Engbeaya; A Lim; D A Patel; M A Ghatei; S R Bloom; W S Dhillo
Journal:  J Clin Endocrinol Metab       Date:  2013-09-12       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.